Dornase alfa during lower respiratory tract infection post-lung transplantation: a randomized controlled trial.
Adult
Anti-Bacterial Agents
/ administration & dosage
Bronchiectasis
/ complications
Cystic Fibrosis
/ complications
Deoxyribonuclease I
/ administration & dosage
Female
Humans
Length of Stay
Lung Diseases
/ complications
Lung Diseases, Interstitial
/ complications
Lung Transplantation
/ adverse effects
Male
Middle Aged
Nebulizers and Vaporizers
Patient Readmission
Patient Safety
Prospective Studies
Pulmonary Disease, Chronic Obstructive
/ complications
Quality of Life
Recombinant Proteins
/ administration & dosage
Respiratory Tract Infections
/ complications
Spirometry
expectorants
humans
lung diseases
physical therapy modalities
respiratory therapy
sputum
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
06
08
2018
revised:
09
10
2018
accepted:
07
01
2019
pubmed:
12
1
2019
medline:
13
2
2020
entrez:
12
1
2019
Statut:
ppublish
Résumé
Lung transplant (LTx) recipients are at risk of lower respiratory tract infection (LRTI), while altered physiology may lead to difficulty clearing sputum. Mucoactive agents alter sputum properties and facilitate mucociliary clearance; however, there are no randomized controlled trials (RCTs) studying this post-LTx. This RCT evaluated the safety and efficacy of nebulized dornase alfa during LRTI post-LTx. Inpatient adults with LRTI and abnormal sputum following bilateral sequential LTx were eligible. Participants received 5 ml of isotonic saline, or 2.5 ml of dornase alfa, nebulized once daily for 1 month followed by 2 months symptom diary. Primary outcome was lung clearance index (LCI2%). Secondary outcomes included spirometry, quality of life, readmission, length of stay, self-reported exacerbations, and adverse events at baseline, 1 and 3 months. Thirty-two participated, 16 in each group, baseline mean (SD) FEV
Substances chimiques
Anti-Bacterial Agents
0
Recombinant Proteins
0
Deoxyribonuclease I
EC 3.1.21.1
dornase alfa
EC 3.1.21.1
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
603-613Subventions
Organisme : Dr Carey Denholm and Laura Denholm
Organisme : Alfred Research Trusts
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 Steunstichting ESOT.